Abstract

To fully exploit the potential of kinases as drug targets, novel strategies for the efficient discovery of inhibitors are required. In contrast to the traditional, linear process of inhibitor discovery, high-throughput kinase profiling enables a parallel approach by interrogating compounds against hundreds of targets in a single screen. Compound potency and selectivity are determined simultaneously, providing a choice of targets to pursue that is guided by the quality of lead compounds available, rather than by target biology alone.

Author affiliations

1. David M. Goldstein is at Roche Palo Alto, 3431 Hillview Avenue, R6-201, Palo Alto, California 94304, USA.
2. Nathanael S. Gray is at the Dana–Farber Cancer Institute, Harvard Medical School, Seeley G. Mudd Building 628A, 250 Longwood Avenue, Boston, Massachusetts 02115, USA.
3. Patrick P. Zarrinkar is at Ambit Biosciences, 4215 Sorrento Valley Boulevard, San Diego, California 92121, USA.

Correspondence to: Patrick P. Zarrinkar³ Email: pzarrinkar@ambitbio.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.